News
-
-
COMMUNIQUÉ DE PRESSE
Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million
Newron Pharmaceuticals S.p.A. enters a subscription agreement for up to 2.05 million new shares, aiming to raise EUR 15.0 million. The investment supports CNS therapies development -
-
-
COMMUNIQUÉ DE PRESSE
Newron appoints Margarita Chavez as board advisor
-
COMMUNIQUÉ DE PRESSE
Newron announces H1 2023 results and provides R&D update
-
-
-
COMMUNIQUÉ DE PRESSE
Newron announces Senior Management Team changes
-
COMMUNIQUÉ DE PRESSE
Newron announces AGM 2023 results